United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Has $35.65 Million Position in Zoetis Inc. (NYSE:ZTS)

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund grew its holdings in Zoetis Inc. (NYSE:ZTS) by 19.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 180,637 shares of the company’s stock after buying an additional 28,839 shares during the quarter. Zoetis makes up 1.8% of United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s portfolio, making the stock its 23rd largest position. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Zoetis were worth $35,652,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ZTS. Blue Bell Private Wealth Management LLC increased its stake in shares of Zoetis by 222.5% in the 4th quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after buying an additional 89 shares during the period. Evermay Wealth Management LLC boosted its holdings in Zoetis by 439.3% during the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its holdings in Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares during the period. Worth Asset Management LLC acquired a new position in shares of Zoetis in the 1st quarter valued at $26,000. Finally, Moisand Fitzgerald Tamayo LLC increased its holdings in shares of Zoetis by 105.5% in the third quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after acquiring an additional 96 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now owns 15,723 shares of the company’s stock, valued at $2,725,267.59. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 2,209 shares of company stock valued at $408,453 over the last quarter. 0.15% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ZTS. Piper Sandler reiterated an “overweight” rating and set a $195.00 target price (down previously from $220.00) on shares of Zoetis in a report on Tuesday. StockNews.com downgraded shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, February 20th. Barclays raised their target price on shares of Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. The Goldman Sachs Group boosted their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Finally, Stifel Nicolaus cut their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $221.75.

Zoetis Stock Performance

NYSE ZTS traded down $1.05 during trading on Wednesday, reaching $151.97. The company’s stock had a trading volume of 2,473,279 shares, compared to its average volume of 2,952,470. The firm has a 50 day moving average price of $178.25 and a 200 day moving average price of $180.59. Zoetis Inc. has a 12 month low of $148.48 and a 12 month high of $201.92. The firm has a market capitalization of $69.50 billion, a price-to-earnings ratio of 30.18, a price-to-earnings-growth ratio of 2.29 and a beta of 0.85. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.32 by ($0.08). Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The company had revenue of $2.21 billion during the quarter, compared to the consensus estimate of $2.19 billion. During the same quarter last year, the firm posted $1.15 earnings per share. The company’s quarterly revenue was up 8.5% on a year-over-year basis. As a group, equities analysts anticipate that Zoetis Inc. will post 5.8 EPS for the current fiscal year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be given a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.14%. The ex-dividend date is Thursday, April 18th. Zoetis’s payout ratio is currently 34.12%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.